Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide----1件: 11 💬
2(6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol----1件: 6 💬
3(7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine----1件: 301 💬
4(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE1件: Pyrazole---1件: 75 💬
5(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE1件: Pyrazole---1件: 75 💬
6(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE1件: Pyrazole---1件: 75 💬
7(S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one----1件: 240 💬
80.005% Lacripep----1件: 53 💬
90.01% Lacripep----1件: 53 💬
100.02% Fm, SH----1件: 53 💬
110.02% Fm, SH, 0.05% CsA----1件: 53 💬
120.02% Fm, SH, AS----1件: 53 💬
130.04 mg Lu AE04621----1件: 6 💬
140.05%cyclosporin eye drop1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 38 💬
150.08 mg Lu AE04621----1件: 6 💬
160.15mg KPG-818 dose----1件: 49 💬
170.6mg KPG-818 dose----1件: 49 💬
180.8 mg Lu AE04621----1件: 6 💬
190002-8971----1件: 70 💬
20009-0----1件: 6 💬
210109-0012A 100 mg/ml----1件: 46 💬
220109-0012A 25 mg/ml----1件: 46 💬
230109-0012A 50 mg/ml----1件: 46 💬
240114-0006B----2件: 46, 96 💬
251 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
261 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
271 ml 0.9 % NaCl----1件: 46 💬
281,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c----1件: 46 💬
291.0 mg Lu AE04621----1件: 6 💬
301.0 mg rasagiline mesylate1件: Rasagiline2件: Rasagiline ,
Rasagiline tartrate 💬
1件: MAOB 💬14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6 💬
311.0 mg RPC103----1件: 97 💬
321.0 mg RPC1063----1件: 97 💬
331.0 MIU IL-2 per day1件: Human interleukin-2---1件: 2 💬
341.0mg RPC1063----1件: 13 💬
351.2 mg ZGN-440 for injectable suspension----1件: 193 💬
361.8 mg ZGN-440 for injectable suspension----1件: 193 💬
37100mcg rhPTH(1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
3814C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration----3件: 13, 96, 97 💬
3915 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
4015 mg QD PF-066497511件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
4115-0 H20----2件: 6, 19 💬
4218F-OP-801----1件: 2 💬
431[(6- Allyl- 8beta- erg----1件: 6 💬
441[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-----1件: 6 💬
451[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea----1件: 6 💬
461[(6- Allyl- 8ß- erg----1件: 6 💬
471[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-----1件: 6 💬
481[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea----1件: 6 💬
492 x 10 mg Natura-alpha capsules----1件: 97 💬
502.0 MIU IL-2 per day1件: Human interleukin-2---1件: 2 💬
5120 mg BID of PF-02545920----1件: 8 💬
5220mg/0.5ml GA----1件: 13 💬
5320mg/0.5ml glatiramer acetate2件: Acetate,
Glatiramer
---1件: 13 💬
54225mg SHP647 (PF-00547659)----1件: 97 💬
5525mcg rhPTH(1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
5629180.00.00, 34681.00.00, 34681.01.00, 34681.02.00----1件: 113 💬
572mg KPG-818 dose----1件: 49 💬
583 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
593 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
603- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate----1件: 6 💬
613-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid----1件: 93 💬
6240 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL----1件: 107 💬
6344/154/85-C----1件: 50 💬
6444/196/81-C----1件: 50 💬
655% lidocaine/5 mg/ml 0.02% estradiol compound cream2件: Estradiol,
Lidocaine
3件: Estradiol ,
Lidocaine ,
Lidocaine hydrochloride monohydrate 💬
7件: ESR1,
ESR2,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
13件: Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬1件: 226 💬
665,6,7,8-tetrahydrobiopterin1件: Sapropterin1件: Sapropterin 💬--1件: 240 💬
67500 0500 0----1件: 19 💬
6850mcg rhPTH(1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
6952069.00.01----1件: 13 💬
70549-0261/F02-01----2件: 96, 97 💬
71552-02----2件: 53, 299 💬
726036937.00.01----1件: 6 💬
737 mg QD to 15 mg QD PF-066497511件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
747 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
7570930.00.00----1件: 46 💬
7675mg SHP647 (PF-00547659)----1件: 97 💬
7789 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled)----1件: 19 💬
7889Zr]Zr-Df-crefmirlimab berdoxam----2件: 51, 53 💬
7998-92-0----1件: 107 💬
80[124I]IB PF 06687234----2件: 96, 97 💬
81[18F]MNI-815 (MNI-815)----1件: 5 💬
82[18F]P17-059----1件: 6 💬
83[F-18]SDM-8----1件: 13 💬
84[Zr-89]Oxine-labeled leukocytes PET/MRI1件: Oxyquinoline1件: Oxyquinoline 💬--1件: 13 💬
85A4250-015----1件: 297 💬
86A: PTH (1-84)----1件: 235 💬
87AAV2/8.TBG.hARSB----1件: 19 💬
88AAV9 BBP-8121件: BBP-812---1件: 307 💬
89AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies----1件: 19 💬
90AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies----1件: 19 💬
91Abacavir sulfate, Lamivudine and Zidovudine4件: Abacavir,
Lamivudine,
Sulfate ion,
Zidovudine
3件: Lamivudine ,
Zidovudine ,
Abacavir 💬
--1件: 265 💬
92ABBV-006----1件: 97 💬
93ABBV-066----2件: 96, 97 💬
94ABBV-0805----1件: 6 💬
95ABBV-105, A-1519938.0----1件: 46 💬
96ABBV-8E12----2件: 5, 7 💬
97ABT-874----1件: 96 💬
98ABT-874/Human monoclonal antibody against IL-12----1件: 13 💬
99ABY-035----1件: 271 💬
100ACE-011----1件: 86 💬
101ACE-011 / MK - 7962----1件: 86 💬
102ACE-011 / MK-7962----1件: 86 💬
103ACE-011/ MK-7962----1件: 86 💬
104ACE-031 (Extension of cohort 1 from core study, A031-03)----1件: 113 💬
105ACE-031 (Extension of cohort 2 from core study, A031-03)----1件: 113 💬
106ACE-031 (Extension of cohort 3 from core study, A031-03)----1件: 113 💬
107ACE-031 0.5 mg/kg q4wk----1件: 113 💬
108ACE-031 1.0 mg/kg q2wk----1件: 113 💬
109ACE-083----2件: 10, 113 💬
110ACER-002 (celiprolol) 200 mg BID1件: Celiprolol1件: Celiprolol 💬1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 168 💬
111ACH-0144471----2件: 62, 222 💬
112ACH-0144471 compresse----1件: 222 💬
113ACH-0145228----1件: 62 💬
114ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable----1件: 299 💬
115ACP-001----1件: 78 💬
116ACP-001 (TransCon hGH)----1件: 78 💬
117ACP-011----1件: 78 💬
118ACT - 064992----1件: 86 💬
119ACT-050089----1件: 86 💬
120ACT-050089 (Ro 61-0612)----1件: 86 💬
121ACT-064992----5件: 51, 85, 86, 88, 210 💬
122ACT-064992 (macitentan)1件: Macitentan1件: Macitentan 💬2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 85 💬
123ACT-064992 / JNJ-67896062----1件: 86 💬
124ACT-064992/ JNJ-67896062----1件: 86 💬
125ACT-064992D----1件: 86 💬
126ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen---2件: 61, 62 💬
127Acthar 80 unit injection1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 66 💬
128ACTHAR Gel 80 units twice weekly.1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
129Acthar high dose (80 U)1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 49 💬
130ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen---2件: 62, 66 💬
131Active Investigational Treatment ENT-01----1件: 6 💬
132ACZ885, 150mg/1.0ml----2件: 266, 267 💬
133AD-810N (zonisamide)1件: Zonisamide1件: Zonisamide 💬8件: CACNA1G,
CACNA1H,
CACNA1I,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus 💬1件: 6 💬
134Ad26.COV2-S.02----1件: 299 💬
135Adalimumab 80 mg1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
136Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
137Adderall XR----1件: 13 💬
138Adderall XR 10 mg----1件: 13 💬
139Adderall XR 5mg----1件: 13 💬
140ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
141Adempas 0.125 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 299 💬
142Adempas 0.5 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299 💬
143Adempas 0.5 mg Film Coated Tablet1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
144Adempas 1.0 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299 💬
145Adempas 2.0 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299 💬
146Adempas® 0.5 mg film-coated tablets1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
147Adempas® 1.0 mg film-coated tablets1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
148Adempas® 2.0 mg film-coated tablets1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
149Adempas¿ 0.5 mg compressa rivestita con film1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
150Adempas¿ 1.01件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
151Adempas¿ 2.0 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
152ADENO-ASSOCIATED VIRAL (AAV) SEROTYPE 8 (AAV2/8) VECTOR WITH LIVER-SPECIFIC THYROXINE-BINDING GLOBULIN (TBG) PROMOTER, DRIVING THE EXPRESSION OF THE HUMAN ARSB GENE1件: Levothyroxine1件: Levothyroxine 💬2件: THRA,
THRB 💬
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬1件: 19 💬
153Adeno-associated viral vector serotype 8 containing the human MD1 gene----1件: 113 💬
154Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector----1件: 19 💬
155Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector----1件: 19 💬
156ADS-001----1件: 231 💬
157Advagraf 0,5mg1件: Tacrolimus2件: Tacrolimus ,
Tacrolimus 💬
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
158ADVM-043----1件: 231 💬
159AEZS-130 (formerly ARD-07)----1件: 78 💬
160AGS-009----1件: 49 💬
161AK106-0016161件: AK106-001616---1件: 46 💬
162Alemtuzumab 0.2 mg1件: Alemtuzumab1件: Alemtuzumab 💬1件: CD52 💬-2件: 65, 164 💬
163Alemtuzumab 0.3 mg1件: Alemtuzumab1件: Alemtuzumab 💬1件: CD52 💬-2件: 65, 164 💬
164ALK-001----1件: 301 💬
165ALK-001 (No generic name)----1件: 301 💬
166ALKS 8700----1件: 13 💬
167ALKS 8700 Delayed Release (DR)1件: Manganese citrate---1件: 13 💬
168ALKS 8700 Delayed Release (DR) Capsule1件: Manganese citrate---1件: 13 💬
169Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)----1件: 6 💬
170Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)----1件: 6 💬
171Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)----1件: 6 💬
172Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)----1件: 6 💬
173ALRN-5281 0.015 mg/kg----1件: 78 💬
174ALRN-5281 0.05 mg/kg----1件: 78 💬
175ALRN-5281 0.15 mg/kg----1件: 78 💬
176ALX-0061----2件: 46, 49 💬
177ALX-0061 150 mg/mL----1件: 49 💬
178ALX-0061 Nanobody----1件: 46 💬
179ALX-0081----1件: 64 💬
180ALX-009----1件: 299 💬
181ALX-0600----1件: 96 💬
182ALXN2040 (ACH-0144471)----1件: 62 💬
183AM-01----1件: 51 💬
184AMB-05X----1件: 85 💬
185AMG 811----1件: 49 💬
186AMG 827----2件: 46, 96 💬
187AMG 827 140 mg----1件: 46 💬
188AMG 827 210 mg----2件: 46, 96 💬
189AMG 827 350 MG----1件: 96 💬
190AMG 827 70 mg----1件: 46 💬
191AMG 827 700 MG----1件: 96 💬
192ANA001XHCl (Syntagon) or VEXA-04 (Patheon)----1件: 156 💬
193Anti-Beta Interferon (PF-06823859)----1件: 50 💬
194Anti-IL-20 (109-0012)1件: Fletikumab1件: Fletikumab 💬1件: IL20 💬3件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
195AP1189, 80 mg----1件: 46 💬
196Apomorphine 0.25% (2.5mg/ml)1件: Apomorphine1件: Apomorphine 💬2件: DRD1,
DRD2 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
197Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed1件: Apomorphine1件: Apomorphine 💬2件: DRD1,
DRD2 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
198Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed1件: Apomorphine1件: Apomorphine 💬2件: DRD1,
DRD2 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
199Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed1件: Apomorphine1件: Apomorphine 💬2件: DRD1,
DRD2 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
200Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed1件: Apomorphine1件: Apomorphine 💬2件: DRD1,
DRD2 💬
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
201Apraclonidine Hcl 0.5% Oph Soln1件: Apraclonidine1件: Apraclonidine 💬3件: ADRA2A,
ADRA2B,
ADRA2C 💬
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 11 💬
202Apriso 0.375G ER CAP----1件: 97 💬
203ARCT-032----1件: 299 💬
204ARCT-810----1件: 251 💬
205Asacol 800 mg (mesalamine)1件: Mesalazine1件: Mesalamine 💬--1件: 97 💬
206Asacol 800 mg tablet1件: Mesalazine1件: Mesalamine 💬--1件: 97 💬
207Asacol 800mg tablet1件: Mesalazine1件: Mesalamine 💬--1件: 97 💬
208ASF-1096 Cream 0.25%----1件: 49 💬
209ASF-1096 Cream 0.5%----1件: 49 💬
210ASF-1096 Cream 1.0%----1件: 49 💬
211Aspirin 81mg tablet1件: Acetylsalicylic acid1件: Aspirin 💬2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46 💬
212ATN-103 80 mg q4wks----1件: 46 💬
213ATN-103 80 mg q8wks----1件: 46 💬
214Atorvastatin 80mg1件: Atorvastatin1件: Atorvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 97 💬
215ATYR1923 1.0 mg/kg1件: ATYR1923---1件: 84 💬
216ATYR1923 3.0 mg/kg1件: ATYR1923---1件: 84 💬
217ATYR1923 5.0 mg/kg1件: ATYR1923---1件: 84 💬
218AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA1件: Teriflunomide1件: Teriflunomide 💬1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬1件: 13 💬
219Autologous cardiac stem cells (JRM-001)----2件: 210, 211 💬
220AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung1件: Bevacizumab1件: Bevacizumab 💬1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 227 💬
221Avonex 30 microgram/0.5 ml Solution for Injection1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
222AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
223Avonex 30 microgramos/0.5 ml Solución para inyección1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
224AVONEX 30 µg/0,5 ml solution for injection1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
225AVONEX IM 4SIR 30MCG/0,5ML 4AG1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
226AVONEX*IM 4SIR 30MCG/0,5ML+4AG1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
227Avonex/Zocor1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
228Avonex® monotherapy (6.0 MIU administered i.m. each week)1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
229AVR-RD-01----1件: 19 💬
230AVR-RD-02----1件: 19 💬
231AVTX-803----1件: 65 💬
232AVTX-803 (L-Fucose)1件: Fucose---1件: 65 💬
233AZD9567 80 mg----1件: 46 💬
234Azithromycin (Zitromax°)1件: Azithromycin2件: Azithromycin ,
Azithromycin 💬
--1件: 228 💬
235BAF312 0,25 mg tablet----1件: 13 💬
236BAF312 0,5 mg tablet----1件: 50 💬
237BAF312 0.25 mg----1件: 50 💬
238BAF312 0.25 mg tablet----1件: 50 💬
239BAF312 0.25mg tablet----1件: 50 💬
240BAF312 0.5 mg----1件: 50 💬
241BAF312 0.50 mg----1件: 50 💬
242BAY 63-2521 0.06 %----1件: 86 💬
243BAY 63-2521 0.3 %----1件: 86 💬
244BAY 63-2521 coated tablets 0.5 mg----2件: 86, 88 💬
245BAY 63-2521 IR coated tablet 1.0 mg----1件: 88 💬
246BAY 63-2521 IR coated tablet 2.0 mg----1件: 88 💬
247BAY 63-2521 IR tablet 0.5 mg----1件: 88 💬
248BAY 63-2521 IR tablet 1.0 mg----1件: 88 💬
249BAY 63-2521 IR tablet 2.0 mg----1件: 88 💬
250BAY 63-2521 IR tablets 0.5 mg----1件: 86 💬
251BAY 63-2521 IR tablets 1.0 mg----1件: 86 💬
252BAY 63-2521 IR tablets 2.0 mg----1件: 86 💬
253BAY 63-2521 tablets 0.5 mg----2件: 86, 88 💬
254BAY 85-8501----1件: 299 💬
255BAY85-8501----1件: 299 💬
256BBP-8121件: BBP-812---1件: 307 💬
257BBT-877----1件: 85 💬
258BBT-877, Multiple doses----1件: 85 💬
259BBT-877, Single dose----1件: 85 💬
260BCD-033 (interferon beta 1a)2件: Human interferon beta,
Interferon beta-1a
1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
261BCD-054 180 mcg----1件: 13 💬
262BCD-054 240 mcg----1件: 13 💬
263BCD-055----2件: 46, 271 💬
264BCD-063----1件: 13 💬
265BCD-085----2件: 93, 271 💬
266BCD-089----1件: 46 💬
267BCD-089, 162 mg, s/c, q2w----1件: 46 💬
268BCD-089, 162 mg, s/c, qw----1件: 46 💬
269BCG20-0134----1件: 13 💬
270Belantamab mafodotin 1.9 mg/kg (8 weeks)1件: Belantamab mafodotin1件: Belantamab mafodotin 💬10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28 💬
271Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages1件: Belantamab mafodotin1件: Belantamab mafodotin 💬10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28 💬
272Belantamab mafodotin 2.5 mg/kg (8 weeks)1件: Belantamab mafodotin1件: Belantamab mafodotin 💬10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28 💬
273BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML1件: Interferon beta-1b1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
274BETAFERON SC 15F 0,25MG 15SIR1件: Interferon beta-1b1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
275BETAFERON*15CONFEZ 0,25MG/ML+1件: Interferon beta-1b1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
276Betaloc ZOK 100, 95 mg----1件: 113 💬
277Betaloc ZOK 25, 23,75 mg----1件: 113 💬
278BEVACIZUMAB ZIRCONIUM ZR-892件: Bevacizumab,
Bevacizumab zirconium Zr-89
1件: Bevacizumab 💬1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34 💬
279BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle,
Neisseria meningitidis serogroup b fhbp fusion protein antigen,
Neisseria meningitidis serogroup b nada protein antigen,
Neisseria meningitidis serogroup b nhba fusion protein antigen
---1件: 66 💬
280BGC20-0134----1件: 13 💬
281BGJ398 (also known as BBP-831)----1件: 276 💬
282BGP-014----1件: 97 💬
283BGP-014 Capsules----1件: 97 💬
284BGX-0214----1件: 46 💬
285BHT-3009 0.5 mg----1件: 13 💬
286BHT-3009-01----1件: 13 💬
287BHV-0223----1件: 2 💬
288BIIB 017----1件: 13 💬
289BIRT 2584 XX----1件: 13 💬
290BIVV001 (rFVIIIFc-VWF-XTEN)----1件: 288 💬
291BL-8040----1件: 60 💬
292Blood coagulation factor XIII1件: Factor XIII (human)---1件: 51 💬
293BMN 044----1件: 113 💬
294BMN 044 IV 6 mg/kg----1件: 113 💬
295BMN 044 IV 9 mg/kg----1件: 113 💬
296BMN 044 SC 6 mg/kg----1件: 113 💬
297BMN 0451件: BMN-045---1件: 113 💬
298BMN 053----1件: 113 💬
299BMS-8173991件: BMS-817399---1件: 46 💬
300BMS-986089-01 (RO7239361) , anti-myostatin----1件: 113 💬
301BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113 💬
302BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL)----1件: 113 💬
303BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113 💬
304BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113 💬
305BMS-986089-01 (RO7239361), anti-myostatin----1件: 113 💬
306BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113 💬
307BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)----1件: 113 💬
308BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113 💬
309BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113 💬
310BMS-986089-01, Anti-myostatin----1件: 113 💬
311BMS-986256-06, TLR7/8 Antagonist1件: Afimetoran1件: Afimetoran 💬--1件: 49 💬
312Botulinum Toxin: Xeomin1件: Botulinum toxin type A1件: Botulinum toxin type A 💬1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 6 💬
313BPLG-003----1件: 78 💬
314BPN14770/ zatolmilast1件: Zatolmilast1件: Zatolmilast 💬1件: PDE4D 💬5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬1件: 206 💬
315BRL-049653----1件: 46 💬
316BT-11 1,000 mg----1件: 96 💬
317BT051 800 mg----1件: 97 💬
318Budesonide ( Zentacort Capsules 3mg )1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
319Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
320Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
321Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
322Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
323Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
324BUET 0.5 mg----1件: 98 💬
325BUL 0.5 mg----1件: 98 💬
326Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)1件: Bupivacaine1件: Bupivacaine 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 46 💬
327Bupivacaine Injection 0.5%1件: Bupivacaine1件: Bupivacaine 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 168 💬
328Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine3件: Bupivacaine,
Clonidine,
Epinephrine
3件: Epinephrine ,
Clonidine ,
Bupivacaine 💬
14件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 70 💬
329Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml1件: Sufentanil1件: Sufentanil 💬1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 70 💬
330BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI1件: Busulfan1件: Busulfan 💬--2件: 19, 65 💬
331BUU 0.4mg/ml----1件: 98 💬
332C-028380----1件: 106 💬
333C-82 Topical Gel, 1%----1件: 51 💬
334Cabaseril, 1,0 mg Tablette----1件: 6 💬
335Cabaseril, 2,0 mg Tablette----1件: 6 💬
336CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI2件: Calcium,
Calcium carbonate
2件: Calcium carbonate ,
Calcium carbonate 💬
--1件: 274 💬
337CALY-002----1件: 98 💬
338Camoteskimab (CERC-007, AVTX-007, AEVI-007)----1件: 107 💬
339Caplacizumab (ALX-0081)1件: Caplacizumab1件: Caplacizumab 💬1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
340Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)2件: Caplacizumab,
Von Willebrand factor human
1件: Caplacizumab 💬1件: VWF 💬8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
341Carnosine, capsulle, 2 g/day, 8 weeks1件: Carnosine---1件: 13 💬
342Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)----1件: 85 💬
343Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler1件: Aztreonam1件: Aztreonam 💬--1件: 299 💬
344CB-01-02----1件: 97 💬
345CB-01-05-MMX----1件: 97 💬
346CC-220 0.3 mg Daily----1件: 84 💬
347CC-220 0.6mg Daily----1件: 84 💬
348CCP-020----1件: 36 💬
349Cenerimod 0.5 mg1件: Cenerimod1件: Cenerimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 49 💬
350CER-001----1件: 79 💬
351CERC-006----1件: 278 💬
352Certican 0,51件: Everolimus1件: Everolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 228 💬
353Certican 0,5 mg Tabletten1件: Everolimus1件: Everolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 228 💬
354Certican 0,75mg1件: Everolimus1件: Everolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 228 💬
355Certican 0,75mg Tabletten1件: Everolimus1件: Everolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 228 💬
356Cholecalciferol 10,000 IU1件: Cholecalciferol1件: Cholecalciferol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96 💬
357Cholecalciferol and C. Xanthorrhiza1件: Cholecalciferol1件: Cholecalciferol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 49 💬
358CHS-0214----1件: 46 💬
359CJNJ-68150420-ZZZ-G001 (ACT- 064992D)----1件: 86 💬
360CJNJ-68150420-ZZZ-G001 (ACT-064992D)----1件: 86 💬
361CJNJ-68150420-ZZZ-G001(ACT-064992D)----1件: 86 💬
362Clobetasol 0.05% ointment1件: Clobetasol1件: Clobetasol 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 39 💬
363Clobetasol 0.05% Topical Ointment1件: Clobetasol1件: Clobetasol 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
364Clonidine HCl CF 0,150 mg, tabletten1件: Clonidine1件: Clonidine 💬3件: ADRA2A,
ADRA2B,
ADRA2C 💬
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 78 💬
365Cnp-MS-0601----1件: 13 💬
366CNSA-001----1件: 240 💬
367CNT-02----1件: 160 💬
368CNTO 888 1 mg/kg----1件: 85 💬
369CNTO 888 15 mg/kg----1件: 85 💬
370CNTO 888 5 mg/kg----1件: 85 💬
371Coagulation factor X1件: Coagulation factor X human---1件: 288 💬
372Coagulation factor XIII1件: Factor XIII (human)---1件: 288 💬
373Cohort 1 0.225g----1件: 240 💬
374Cohort 1: 1.0 x 10^8 PolyTregs----1件: 35 💬
375Cohort 2 0.75g----1件: 240 💬
376Cohort 2: 2.5x10^8 PolyTregs----1件: 35 💬
377Combivir (zidovudine [AZT] / lamivudine [3TC])2件: Lamivudine,
Zidovudine
2件: Lamivudine ,
Zidovudine 💬
--1件: 265 💬
378Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion1件: Tozinameran1件: Tozinameran 💬--1件: 13 💬
379Compressa effervescente 0,5 mg di budesonide per uso orodispersibile1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
380Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d1件: Conjugated estrogens1件: Estrogens, conjugated 💬--1件: 49 💬
381Control Group 0.9% Isotonic Saline----1件: 299 💬
382COR-003----1件: 75 💬
383Corticoids+ tocilizumab 8mg/Kg/4 weeks1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
384Corticotrophin 80 units1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 46 💬
385COVID-19 mRNA vaccine Moderna (CX-024414)----4件: 13, 46, 51, 299 💬
386CR845 1.0 mg----1件: 93 💬
387CRC3357, ZK-355322, Leukoton----1件: 299 💬
388CRD-TMH-001----1件: 113 💬
389Creon 10.000, hårde enterokapsler----1件: 299 💬
390Creon 25.000, hårde enterokapsler----1件: 299 💬
391Creon 40.000, hårde enterokapsler----1件: 299 💬
392Creon® 25,000----1件: 299 💬
393CS-0777 tablets----1件: 13 💬
394CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)----1件: 19 💬
395Cudetaxestat (BLD-0409)----1件: 85 💬
396Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg1件: Turmeric---1件: 299 💬
397CVXL-0107----1件: 6 💬
398CX-016492----1件: 245 💬
399CX-017950----1件: 245 💬
400CX-8998----1件: 6 💬
401Cyclosporine 0.09% Ophthalmic Solution1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 53 💬
402Cyclosporine 5 mg/kg bid days 0-141件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬2件: 38, 39 💬
403CYSTADROPS 0.55% eye drops, solution1件: Cysteamine1件: Cysteamine 💬--1件: 19 💬
404Cápsulas de Laquinimod 0.6 mg1件: Laquinimod---1件: 13 💬
405Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088)----1件: 274 💬
406D.3.6.2.1 - valore: 45 / 0.45 mg/ml----1件: 97 💬
407Dark chocolate (85% cocoa)1件: Cocoa---1件: 6 💬
408DAS-001----1件: 11 💬
409Deferiprone 80 mg/mL oral solution1件: Deferiprone1件: Deferiprone 💬--1件: 120 💬
410Deferiprone 80 mg/mL oral solution (Ferriprox)1件: Deferiprone1件: Deferiprone 💬--1件: 120 💬
411Dekristol 20.000 ie----1件: 96 💬
412Descartes-08----1件: 11 💬
413Desmotabs® 0,2 mg Tabletten----1件: 6 💬
414Desmotabs® 0,2mg Tabletten----1件: 6 💬
415Dexamethasone 0,1 mg Tablets1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
416Dexamethasone 0,5mg1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 84 💬
417Dexamethasone 0.5mg Tablet1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
418Dexamethasone 0.5mg/5ml solution1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162 💬
419Dexamethasone 0.5mg/5ml solution in Mucolox™1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162 💬
420Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 235 💬
421Digoxin 0.25 mg1件: Digoxin1件: Digoxin 💬4件: ATP1A1,
ATP1A2,
ATP1A3,
ATP1A4 💬
18件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 46 💬
422Diovan 80 mg1件: Valsartan1件: Valsartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 58 💬
423DIURF-006----1件: 81 💬
424Dotarem 0,5mmol/ml,1件: Gadoteric acid1件: Gadoteric acid 💬--1件: 13 💬
425Doxepin and Zopiclone2件: Doxepin,
Zopiclone
2件: Zopiclone ,
Doxepin 💬
19件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ,
HRH1,
SLC6A2,
SLC6A4 💬
10件: Calcium signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction 💬1件: 6 💬
426Drug-Carbamazepine (Tegretol XR)1件: Carbamazepine1件: Carbamazepine 💬5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 231 💬
427Dulaglutide 0.75Mg/0.5Ml Inj Pen1件: Dulaglutide1件: Dulaglutide 💬1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 299 💬
428Dummy Qing Re Huo Xue (QRHX)----1件: 46 💬
429DUOC-01----3件: 13, 19, 20 💬
430DX-890----1件: 299 💬
431E5501 40 mg 2 x 20-mg tablets, orally, fasted----1件: 63 💬
432E5501 40 mg 2 x 20-mg tablets, orally, with food----1件: 63 💬
433E5501 40mg 2 x 20-mg tablets, orally, fasted----1件: 63 💬
434Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml----1件: 96 💬
435Ecologic 825----1件: 97 💬
436Efexor XL 75 mg----1件: 46 💬
437Efexor XL 75 mg (venlafaxine)1件: Venlafaxine1件: Venlafaxine 💬2件: SLC6A2,
SLC6A4 💬
2件: Serotonergic synapse, Synaptic vesicle cycle 💬1件: 46 💬
438Elafibranor 80 mg1件: Elafibranor1件: Elafibranor 💬1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬2件: 93, 94 💬
439Elafibranor 80mg1件: Elafibranor1件: Elafibranor 💬1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
440ELX-021件: ELX-02---3件: 19, 218, 299 💬
441EMD 87580----1件: 113 💬
442EMEA/H/C/000109----1件: 203 💬
443EMEA/H/C/000125----1件: 299 💬
444EMEA/H/C/000240----2件: 96, 97 💬
445EMEA/H/C/000481----1件: 97 💬
446EMEA/H/C/000638----1件: 113 💬
447EMEA/H/C/000701----1件: 50 💬
448EMEA/H/C/000712----1件: 227 💬
449EMEA/H/C/002576----1件: 96 💬
450EMEA/H/C/002778----1件: 96 💬
451EMEA/H/C/004214----1件: 46 💬
452ENB-0040----1件: 172 💬
453ENBREL*SC 4SIR 25MG 0,5ML+8TAM1件: Etanercept1件: Etanercept 💬2件: LTA,
TNF 💬
67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
454ENBREL*SC 4SIR 50MG 1ML+8TAMP1件: Etanercept1件: Etanercept 💬2件: LTA,
TNF 💬
67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
455ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA----1件: 51 💬
456ENDOPROST 0,05MG/0,5ML 1F----1件: 51 💬
457ENDOPROST 50*INFUS 1F 0,050MG/----1件: 51 💬
458ENT-01----1件: 6 💬
459EPARMEFOLIN 30 CPR 0,1/0,5MG----1件: 13 💬
460EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)----1件: 46 💬
461EPI-hNE4 DX-890----1件: 299 💬
462ERB-041----3件: 46, 96, 226 💬
463Etanercept 50 mg sc day 0 and day 31件: Etanercept1件: Etanercept 💬2件: LTA,
TNF 💬
67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 38, 39 💬
464Ethylhydrogenfumarat, Zinksalz----1件: 49 💬
465EU Orphan Designation Number EU/3/02/120----1件: 299 💬
466EU/1/03/256/001----1件: 107 💬
467EU/1/03/268/002----1件: 96 💬
468EU/1/06/362/003: 5µg (1 pen)----1件: 193 💬
469EU/1/07/389/001----1件: 107 💬
470EU/1/08/454/001-002, EU/1/08/454/005-007----1件: 13 💬
471EU/1/14/980/002----1件: 269 💬
472EU/1/14/980/003----1件: 269 💬
473EU/1/95/003/005-010----1件: 13 💬
474EU/1/97/033/002----1件: 13 💬
475EU/1/98/063/001-003----1件: 13 💬
476EU/1/98/063/004-006----1件: 13 💬
477EU/1/99/116/003----1件: 96 💬
478EU/1/99/126/001----1件: 107 💬
479EU/1/99/126/017----1件: 46 💬
480EU/1/99/126/020----1件: 46 💬
481EU1/97/031-032----1件: 18 💬
482EU1/97/031/031-032----1件: 18 💬
483EUR-1008 25,000 Units----1件: 299 💬
484EVP-0334----1件: 127 💬
485Exelon 3,0 mg Hartkapseln1件: Rivastigmine1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 5 💬
486Exelon 6,0 mg Hartkapseln1件: Rivastigmine1件: Rivastigmine 💬1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 5 💬
487Experimental: Seladelpar / MBX-8025 200 mg1件: Seladelpar1件: Seladelpar 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 93 💬
488Experimental: Seladelpar / MBX-8025 50 mg1件: Seladelpar1件: Seladelpar 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 93 💬
489F-18 FEDAA1106 (BAY85-8101)----1件: 13 💬
490FACTOR X1件: Coagulation factor X human---1件: 288 💬
491Factor XIIa antagonist monoclonal antibody----1件: 85 💬
492Factor XIII1件: Factor XIII (human)---3件: 51, 97, 288 💬
493Factor XIII Concentrate (Human)1件: Factor XIII (human)---1件: 288 💬
494Factor XIII Concentrate (Human), Pasteurized1件: Factor XIII (human)---1件: 288 💬
495Fasudil (WP-0512)1件: Fasudil1件: Fasudil 💬2件: ROCK1,
ROCK2 💬
23件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 2 💬
496FCX-007----1件: 36 💬
497FCX-013----1件: 51 💬
498Fibrogammin®P, coagulation factor XIII concentrate (Human)1件: Factor XIII (human)---1件: 51 💬
499Fingolimod 0.5 mg1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
500Fingolimod 0.5mg1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
501FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE1件: Amifampridine1件: Amifampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬2件: 3, 11 💬
502Fosmetpantotenate (RE-024)----1件: 120 💬
503FP-CYA-050----1件: 97 💬
504FP-CYA-053----1件: 97 💬
505FRM-0334----1件: 127 💬
506Fultium-D3 800IU capsules----1件: 274 💬
507GA Depot 80 mg----1件: 13 💬
508Gaboxadol (HLX-0206)1件: Gaboxadol1件: Gaboxadol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 206 💬
509Gaboxadol monohydrate 0.5 mg1件: Gaboxadol1件: Gaboxadol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 201 💬
510Gaboxadol monohydrate 0.5 mg (intended commercial formulation)1件: Gaboxadol1件: Gaboxadol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 201 💬
511Gaboxadol monohydrate 0.5 mg capsule1件: Gaboxadol1件: Gaboxadol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 201 💬
512Gadovist 1.0 mmol/ml Injektionslösung1件: Gadobutrol1件: Gadobutrol 💬--1件: 13 💬
513GB-0998----1件: 50 💬
514GB-0998 (Intravenous immunoglobulin)----1件: 11 💬
515GC1111_1.0mg/kg----1件: 19 💬
516GDC-01341件: GDC-0134---1件: 2 💬
517GDC-0853----3件: 13, 46, 49 💬
518GDC-0853 RO7010939----3件: 13, 46, 49 💬
519GED-0301----2件: 96, 97 💬
520GED-0507-34-LEVO1件: GED-0507-34-Levo---1件: 97 💬
521GED-0507-34-Levo 160 mg1件: GED-0507-34-Levo---1件: 97 💬
522GED-0507-34-Levo 80 mg1件: GED-0507-34-Levo---1件: 97 💬
523Gene Therapy-vMCO-010----1件: 301 💬
524Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg----1件: 299 💬
525Genotonorm Miniquick 0,2 mg----1件: 193 💬
526Genotropin Miniquick 0.2mg1件: Somatotropin---3件: 74, 75, 78 💬
527Genotropin Miniquick 0.4mg1件: Somatotropin---3件: 74, 75, 78 💬
528Genotropin miniquick 0.5 mg, injection----1件: 78 💬
529Genotropin Miniquick 0.6mg1件: Somatotropin---3件: 74, 75, 78 💬
530Genotropin Miniquick 0.8mg1件: Somatotropin---3件: 74, 75, 78 💬
531Genotropin Miniquick 1.0mg1件: Somatotropin---3件: 74, 75, 78 💬
532Gentamicin sulfate 0.1% ointment2件: Gentamicin,
Sulfate ion
1件: Gentamicin 💬--1件: 36 💬
533Gernebcin 80 mg----1件: 299 💬
534GFB-887----1件: 222 💬
535GFI 38518168-AEK-B-007----1件: 46 💬
536GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
537GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
538GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
539GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
540GILENYA 0,5 mg cápsulas duras1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 14 💬
541Gilenya 0,5 mg Hartkapseln1件: Fingolimod1件: Fingolimod 💬1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
542Glatiramer Acetate 20 mg/0.5 mL2件: Acetate,
Glatiramer
---1件: 13 💬
543GLWL-01----1件: 193 💬
544GNR-055----1件: 19 💬
545GNR-055 1.0-2.0-3.0 mg/kg----1件: 19 💬
546GNR-055 2.0 mg/kg----1件: 19 💬
547GNR-055 3.0 mg/kg----1件: 19 💬
548GNR-069----1件: 63 💬
549Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg1件: Golimumab1件: Golimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
550GSK2586184 800mg single and repeat dose----1件: 49 💬
551GTG003.08----1件: 65 💬
552GW-1000-02----1件: 13 💬
553GYLENIA 0,5 mg----1件: 13 💬
554GYPP-06 (GKT137831 free base), C10071301-D----1件: 93 💬
555H5.001CBCFTR----1件: 299 💬
556HBVAXPRO 5 micrograms/0.5 ml1件: Hepatitis B Vaccine (Recombinant)---1件: 46 💬
557HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)1件: Hepatitis B Vaccine (Recombinant)---1件: 46 💬
558Hemay007 800 mg QD group----1件: 46 💬
559Herpes Zoster Subunit (HZ/su) Vaccine----1件: 49 💬
560Herpes Zoster Vaccine----3件: 46, 96, 271 💬
561HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen---3件: 61, 62, 66 💬
562HK-001----1件: 2 💬
563HL-085----1件: 34 💬
564HLADQA1*05A>G screening----2件: 96, 97 💬
565HLB-001----1件: 246 💬
566HMPL-004----2件: 96, 97 💬
567HMPL-004 1800 mg/day----1件: 97 💬
568HMPL-004 2400 mg/day----1件: 97 💬
569HMPL-004 high dose----1件: 97 💬
570HMPL-004 low dose----1件: 97 💬
571Huang qi gui zhi wu wu granule----1件: 46 💬
572Human Coagulation FACTOR X1件: Coagulation factor X human---1件: 288 💬
573Human factor X1件: Coagulation factor X human---1件: 288 💬
574HuMax-CD38, 3003-005----1件: 28 💬
575Humira (adalimumab) 40 mg in 0.4 ml s.c. injection1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
576Humira (adalimumab) 40mg in 0.4 ml s.c. injection1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
577Humira (adalimumab) 40mg in 0.4ml s.c.injection1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
578HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 56, 97 💬
579HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
580HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 46, 96 💬
581Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL)1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
582Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL)1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
583Humira 40 mg/0.8 ml solution for injection1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬4件: 46, 96, 97, 271 💬
584Humira 40 mg/0.8 ml solution for injection for paediatric use1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
585Humira 40mg/0.4ml pre-filled syringe1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96 💬
586Humira 40mg/0.8 ml solution for injection for paediatric use1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
587Humira 40mg/0.8ml solution for injection for paediatric use1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96 💬
588Humira 40mg/0.8ml solution for injection in pre-filled syringe1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
589Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL)1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
590Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
591HUMIRA*SC 2SIR+F 40MG 0,8ML+2T1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 46, 96 💬
592Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
593Hydroxychloroquine (Z0188)1件: Hydroxychloroquine1件: Hydroxychloroquine 💬--1件: 49 💬
594Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment1件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 85 💬
595Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment1件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 85 💬
596Hyperpolarized 129-Xenon gas1件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 85 💬
597Hyperpolarized Xe129----4件: 51, 85, 86, 299 💬
598Hyperpolarized Xenon1件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 299 💬
599Hyperpolarized Xenon 1291件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 299 💬
600Hyperpolarized Xenon gas1件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 299 💬
601Hyperpolarized xenon-1291件: Xenon2件: Xenon ,
Xenon Xe 133 💬
--1件: 299 💬
602Hypertonic saline (7 %) and isotonic saline (0.9%)----1件: 299 💬
603HZN-825----2件: 51, 85 💬
604HZN-825 BID----1件: 51 💬
605HZN-825 QD----1件: 51 💬
606ICP-022----2件: 46, 49 💬
607ICX-RHY-013----1件: 36 💬
608IdeS (0.25 mg/kg)1件: Imlifidase1件: Imlifidase 💬--1件: 64 💬
609IdeS (0.50 mg/kg)1件: Imlifidase1件: Imlifidase 💬--1件: 64 💬
610IFB-088----1件: 2 💬
611IFB-088 50mg/day----1件: 2 💬
612IL-6R Monoclonal Antibody Injection 8mg/kg----1件: 46 💬
613Iloprost therapy up to 2 ng/kg x min1件: Iloprost1件: Iloprost 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 51 💬
614ILV-094----1件: 46 💬
615IMCY-01411件: IMCY-0141---1件: 13 💬
616IMO-8400----1件: 50 💬
617IMO-8400 Dose Group 1----1件: 50 💬
618IMO-8400 Dose Group 2----1件: 50 💬
619IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''.----1件: 96 💬
620IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form----1件: 96 💬
621IMU-838----3件: 13, 96, 97 💬
622IMU-838 (30 mg/day)----1件: 13 💬
623IMU-838 (45 mg/day)----1件: 13 💬
624IMU-838 tablets----1件: 13 💬
625IMU-838-RC----1件: 13 💬
626IMUKIN - 6 FLACONI 0.5 ML 100 MCG----2件: 18, 58 💬
627IMUKIN*SC 6F 0,5ML 100MCG----1件: 18 💬
628Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus----1件: 53 💬
629INALOSSIN - 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO BOMBOLA IN ALLUMINIO CON VALVOLA VI DA 20 LITRI----1件: 294 💬
630INALOSSIN 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO----1件: 294 💬
631INCB050465 0.3 mg1件: Parsaclisib1件: Parsaclisib 💬1件: PIK3CD 💬106件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬1件: 35 💬
632INCB050465 0.3mg1件: Parsaclisib1件: Parsaclisib 💬1件: PIK3CD 💬106件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬1件: 35 💬
633INCB050465 1.0 mg1件: Parsaclisib1件: Parsaclisib 💬1件: PIK3CD 💬106件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬1件: 35 💬
634INCB050465 1.0mg1件: Parsaclisib1件: Parsaclisib 💬1件: PIK3CD 💬106件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬1件: 35 💬
635Infigratinib 0.016 mg/kg1件: Infigratinib1件: Infigratinib 💬3件: FGFR1,
FGFR2,
FGFR3 💬
21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276 💬
636Infigratinib 0.032 mg/kg1件: Infigratinib1件: Infigratinib 💬3件: FGFR1,
FGFR2,
FGFR3 💬
21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276 💬
637Infigratinib 0.064 mg/kg1件: Infigratinib1件: Infigratinib 💬3件: FGFR1,
FGFR2,
FGFR3 💬
21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276 💬
638Infigratinib 0.128 mg/kg1件: Infigratinib1件: Infigratinib 💬3件: FGFR1,
FGFR2,
FGFR3 💬
21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276 💬
639Infigratinib 0.25 mg/kg1件: Infigratinib1件: Infigratinib 💬3件: FGFR1,
FGFR2,
FGFR3 💬
21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276 💬
640Infliximab (BCD-055)1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 271 💬
641Infliximab 7 mg/kg every 8 weeks1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96 💬
642Infliximab and azathioprine combination at week 02件: Azathioprine,
Infliximab
2件: Azathioprine ,
Infliximab 💬
1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96 💬
643Infusion of ADR-001 (Mesenchymal stem cell)----1件: 66 💬
644INN Parathyroid Hormone (1-84) human1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
645INOmax 800ppm mol/mol inhalatiegas1件: Nitric Oxide1件: Nitric oxide 💬--1件: 294 💬
646Interferon beta-1a, 30 µg/0.5 ml2件: Human interferon beta,
Interferon beta-1a
1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
647Interferon beta-1b (Betaferon, BAY 86-5046)2件: Human interferon beta,
Interferon beta-1b
1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
648Interferon beta-1b (Betaferon®, BAY 86-5046)2件: Human interferon beta,
Interferon beta-1b
1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
649Interferon-beta-1b (BETASERON, BAY 86-5046)2件: Human interferon beta,
Interferon beta-1b
1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
650Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-031件: Irbesartan1件: Irbesartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 66, 222 💬
651Irbesartan tablets (NDA 020 757)1件: Irbesartan1件: Irbesartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 66 💬
652Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC1件: Irbesartan1件: Irbesartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
653Isosorbide Dinitrate 80 mg2件: Isosorbide,
Isosorbide dinitrate
2件: Isosorbide ,
Isosorbide dinitrate 💬
--1件: 113 💬
654Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung----1件: 50 💬
655Isotonic saline 0.9%1件: Sodium chloride1件: Sodium chloride 💬--1件: 299 💬
656IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino----1件: 337 💬
657J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----1件: 96 💬
658Jevity 1.0----1件: 2 💬
659JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
660JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
661JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
662JM-010----1件: 6 💬
663JNJ-38518168-ZBQ----1件: 46 💬
664JNJ-38518168-ZBQ - film-coated tablet - 10 mg----1件: 46 💬
665JNJ-38518168-ZBQ - film-coated tablet - 10mg----1件: 46 💬
666JNJ-38518168-ZBQ - film-coated tablet - 3 mg----1件: 46 💬
667JNJ-38518168-ZBQ - film-coated tablet - 30 mg----1件: 46 💬
668JNJ-38518168-ZBQ - film-coated tablet - 30mg----1件: 46 💬
669JNJ-38518168-ZBQ - film-coated tablet - 3mg----1件: 46 💬
670JNJ-67896062 / ACT-064992----2件: 86, 88 💬
671JNJ-67896062/ ACT-064992----2件: 86, 88 💬
672JNJ-67896062/ACT-064922----1件: 86 💬
673JNJ-80202135----4件: 11, 46, 49, 53 💬
674Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
675Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
676JTE-051----1件: 46 💬
677K-832----1件: 46 💬
678Kamada-AAT for Inhalation, 80mg----1件: 231 💬
679KCT-0809 ophthalmic solution----1件: 53 💬
680KINERET*SC 7SIR 100MG 0,67ML1件: Anakinra1件: Anakinra 💬2件: IL1R1,
IL1R2 💬
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬3件: 28, 46, 107 💬
681KM-819----2件: 6, 17 💬
682KPG-818----1件: 49 💬
683KPS-0373----1件: 18 💬
684KPS-0373, High dose----1件: 18 💬
685KPS-0373, Low dose----1件: 18 💬
686Kreon 25 000----1件: 299 💬
687Kreon 25,000 Units----1件: 299 💬
688Kreon® 25,000----1件: 299 💬
689KW-0761----1件: 26 💬
690KW-0761 0.3 mg/kg IV----1件: 26 💬
691KW-6356 X Dose1件: KW-6356---1件: 6 💬
692L-000124467----2件: 13, 46 💬
693L-000124467 (freebase)----1件: 46 💬
694L-000124467-009J (succinat----1件: 46 💬
695L-000883191----1件: 46 💬
696L-001069957----1件: 46 💬
697L-883191----1件: 46 💬
698L03 AB 08----1件: 13 💬
699Lamivudine/Zidovudine2件: Lamivudine,
Zidovudine
2件: Lamivudine ,
Zidovudine 💬
--1件: 265 💬
700Laquinimod 0.31件: Laquinimod---1件: 13 💬
701Laquinimod 0.61件: Laquinimod---1件: 13 💬
702Laquinimod Capsulas 0.6 mg1件: Laquinimod---1件: 13 💬
703Laquinimod Capsules 0.3 mg1件: Laquinimod---1件: 13 💬
704Laquinimod capsules 0.5 mg1件: Laquinimod---2件: 8, 96 💬
705Laquinimod Capsules 0.6 mg1件: Laquinimod---1件: 13 💬
706Laquinimod Cápsulas 0.5 mg1件: Laquinimod---1件: 96 💬
707Laquinimod Tablets 0.3 mg1件: Laquinimod---1件: 13 💬
708LC51-0255----1件: 97 💬
709LDP-02----2件: 96, 97 💬
710Leflunomide 20 mg+prednisone 0.5mg/kg/d2件: Leflunomide,
Prednisone
2件: Prednisone ,
Leflunomide 💬
2件: DHODH,
NR3C1 💬
4件: Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬1件: 66 💬
711LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung1件: Alemtuzumab1件: Alemtuzumab 💬1件: CD52 💬-1件: 13 💬
712Levodopa-Carbidopa XL tablet (M)2件: Carbidopa,
Levodopa
2件: Levodopa ,
Carbidopa 💬
6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬
16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
713Liofen XL----1件: 13 💬
714LJN452, 0,01 mg----1件: 93 💬
715LJN452, 0,03 mg----1件: 93 💬
716LJN452, 0,1 mg----1件: 93 💬
717Local Trade Name, 8mg----1件: 6 💬
718Lonafarnib, Zoledronic Acid, and Pravastatin3件: Lonafarnib,
Pravastatin,
Zoledronic acid
4件: Zoledronic acid ,
Lonafarnib ,
Pravastatin ,
Zoledronic acid 💬
4件: FDPS,
FNTA,
FNTB,
HMGCR 💬
6件: AMPK signaling pathway, Bile secretion, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 333 💬
719Lopinavir/ritonavir + zidovudine + lamivudine4件: Lamivudine,
Lopinavir,
Ritonavir,
Zidovudine
4件: Lamivudine ,
Zidovudine ,
Ritonavir ,
Lopinavir 💬
--1件: 265 💬
720LP-08 20mg----1件: 226 💬
721LP-08 80mg----1件: 226 💬
722LT-02----1件: 97 💬
723LT-02 (modified-release PC pellets)1件: Manganese citrate---1件: 97 💬
724LTS 0.25mg----1件: 46 💬
725LTS 0.5mg----1件: 46 💬
726LTS 1.0mg----1件: 46 💬
727Lu 00-800----1件: 6 💬
728Lumacaftor/ivacaftor 200mg/83mg tablet2件: Ivacaftor,
Lumacaftor
2件: Ivacaftor ,
Lumacaftor 💬
1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299 💬
729Lutein plus Zeaxanthin2件: Lutein,
Zeaxanthin
---1件: 164 💬
730Lym-X-Sorb powder----1件: 299 💬
731MabThera 500 mg Konzentrat zur Herstellung einer Infusionslösung1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
732Macitentan (ACT-064992)1件: Macitentan1件: Macitentan 💬2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86 💬
733Masitinib (3.0)1件: Masitinib1件: Masitinib 💬1件: KIT 💬11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬1件: 2 💬
734Masitinib (6.0)1件: Masitinib1件: Masitinib 💬1件: KIT 💬11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬1件: 2 💬
735Masitinib 6.0 mg1件: Masitinib1件: Masitinib 💬1件: KIT 💬11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬1件: 46 💬
736Mayzent 0,25 mg Filmtabletten1件: Siponimod1件: Siponimod 💬2件: S1PR1,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
737Mayzent 0.25 mg fi1件: Siponimod1件: Siponimod 💬2件: S1PR1,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
738MBM-01----1件: 65 💬
739MBX 8025----1件: 93 💬
740MBX-8025----3件: 79, 93, 94 💬
741MBX-8025 50 mg (Dose Escalation Period 1)----1件: 79 💬
742MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)----1件: 79 💬
743MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)----1件: 79 💬
744MBX-8025, DSIC----1件: 93 💬
745MBX-8025, Formulation 2----1件: 93 💬
746MD-0901----1件: 97 💬
747MDGN-002----1件: 96 💬
748MEDI-570 0.03 MG----1件: 49 💬
749MEDI-570 0.1 MG----1件: 49 💬
750MEDI-570 0.3 MG----1件: 49 💬
751Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d2件: Eflornithine,
Melarsoprol
2件: Melarsoprol ,
Eflornithine 💬
1件: ODC1 💬3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬1件: 65 💬
752Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d2件: Melarsoprol,
Nifurtimox
2件: Melarsoprol ,
Nifurtimox 💬
--1件: 65 💬
753Meloxicam 0.125 mg/kg1件: Meloxicam1件: Meloxicam 💬1件: PTGS2 💬22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46 💬
754Meloxicam 0.25 mg/kg1件: Meloxicam1件: Meloxicam 💬1件: PTGS2 💬22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 46 💬
755Mesenchymal stem cell 0.5----1件: 228 💬
756Mesenchymal stem cell 1.0----1件: 228 💬
757Metformin XR1件: Metformin1件: Metformin 💬2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 67 💬
758Metformine Sandoz 850 mg filmomhulde tabletten1件: Metformin1件: Metformin 💬2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 81 💬
759METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 96 💬
760Methotrexate plus ERB-041 for 12 weeks1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46 💬
761Methylprednisolone 1250 mg/24h x3 days1件: Methylprednisolone1件: Methylprednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 13 💬
762Mezavant XL1件: Mesalazine1件: Mesalamine 💬--1件: 97 💬
763Mezavant XL 1200 mg gastro-resistant prolonged release tablets2件: Manganese citrate,
Mesalazine
1件: Mesalamine 💬--1件: 97 💬
764Mezavant XL 1200 mg gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine
1件: Mesalamine 💬--1件: 97 💬
765Mezavant XL 1200 mg gastro-resistant, prolonged release tablets.2件: Manganese citrate,
Mesalazine
1件: Mesalamine 💬--1件: 97 💬
766Mezavant XL 1200mg gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine
1件: Mesalamine 💬--1件: 97 💬
767Mezavant XL Gastro-resistant, prolonged release tablets2件: Manganese citrate,
Mesalazine
1件: Mesalamine 💬--1件: 97 💬
768MH004 Ia(0.1%)----1件: 46 💬
769MH004 Ia(0.3%)----1件: 46 💬
770MH004 Ib-1(0.1%)----1件: 46 💬
771MH004 Ib-1(0.3%)----1件: 46 💬
772MH004 Ib-2(0.3%)----1件: 46 💬
773MIGLUSTAT (ZAVESCA)1件: Miglustat1件: Miglustat 💬1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬1件: 19 💬
774Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 891件: Deferoxamine1件: Deferoxamine 💬--2件: 51, 53 💬
775MIRAPEXIN*30CPR 0,7MG1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
776Mirdametinib (PD-0325901) oral capsule or dispersible tablet1件: Mirdametinib1件: Mirdametinib 💬2件: MAP2K1,
MAP2K2 💬
89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 34 💬
777MK-0653----1件: 260 💬
778MK-0663----2件: 46, 271 💬
779MK-0859----1件: 79 💬
780MK-08731件: MK-0873---1件: 46 💬
781MK-8259----1件: 97 💬
782MK-8457----1件: 46 💬
783MK-8457 (free acid)----1件: 46 💬
784MK-8457 100 mg----1件: 46 💬
785MK-8808----1件: 46 💬
786MK-8892----1件: 86 💬
787MM-0931件: MM-093---1件: 46 💬
788MN-001----1件: 226 💬
789MN-001 BID----1件: 226 💬
790MN-08 24 mg/day----1件: 86 💬
791MN-08 60 mg/day----1件: 86 💬
792MORAb-022----1件: 46 💬
793MORF-057----1件: 97 💬
794MR-MC-01----1件: 226 💬
795MRA 003 US----1件: 49 💬
796MSC injection 01----1件: 96 💬
797MSC injection 02----1件: 96 💬
798MSC treatment 01----1件: 96 💬
799MSC treatment 02----1件: 96 💬
800MSTC-001 (MS-STAT)----1件: 13 💬
801MT-1303 [0.1]----1件: 13 💬
802MT-1303 [0.2]----1件: 13 💬
803MT-1303 [0.4]----1件: 13 💬
804MTC TRx0014-001 capsules----1件: 127 💬
805MXB-8025----1件: 93 💬
806MYO-0291件: Stamulumab1件: Stamulumab 💬1件: MSTN 💬1件: Cytokine-cytokine receptor interaction 💬1件: 113 💬
807N-0923----1件: 6 💬
808Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 86 💬
809Nabilone 0.25 mg1件: Nabilone1件: Nabilone 💬2件: CNR1,
CNR2 💬
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 6 💬
810NaCl 0.9%----1件: 39 💬
811National Drug Code: 59762-0074----1件: 81 💬
812Natriumchlorid 0,9 %1件: Sodium chloride1件: Sodium chloride 💬--1件: 288 💬
813NBI-827104----1件: 154 💬
814NBTX-001----1件: 6 💬
815NDC0009-0436-01----1件: 78 💬
816NEB/01-07----1件: 299 💬
817NEUPRO 8 mg/24 h parche transdérmico1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
818Neupro 8 mg/24 h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
819Neupro 8mg/24h transdermal patch1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
820NEUPRO*28CER 8MG/24H1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
821NEUPRO*7CER 8MG/24H1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
822Neupro® 8 mg/24 h1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
823NI-0101----1件: 46 💬
824NI-03----1件: 298 💬
825NI-0401 (anti-CD3 mAB)1件: Muromonab---1件: 96 💬
826NI-0501----1件: 107 💬
827NI-071----1件: 46 💬
828NI-0801----1件: 93 💬
829Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)1件: Nicotine1件: Nicotine 💬16件: CHRNA1,
CHRNA10,
CHRNA2,
CHRNA3,
CHRNA4,
CHRNA5,
CHRNA6,
CHRNA7,
CHRNA9,
CHRNB1,
CHRNB2,
CHRNB3,
CHRNB4,
CHRND,
CHRNE,
CHRNG 💬
8件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬1件: 6 💬
830NNC 0109-0000-0012----1件: 46 💬
831NNC 0141-0000-0100----1件: 46 💬
832NNC 0142-0000-0002----2件: 46, 96 💬
833NNC 0151-0000-0000----2件: 46, 49 💬
834NNC 126-0083----1件: 78 💬
835NNC 142-0002----1件: 46 💬
836NNC0109-0012----1件: 46 💬
837NNC0114-0000-0005----1件: 46 💬
838NNC0114-0006----3件: 46, 49, 96 💬
839NNC0142-0000-0002----1件: 96 💬
840NNC0142-0002----1件: 46 💬
841NNC0151-0000-0000----1件: 46 💬
842NNC0195-0092----1件: 78 💬
843NNC0195-0092 10 mg/1.5 ml PDS290-10----1件: 78 💬
844NNC0195-0092 15 mg/1.5 ml PDS290-15----1件: 78 💬
845NNC0195-0092 5 mg/1.5 ml PDS290-10----1件: 78 💬
846NNC0195-0092 DP 6.7 mg ml 3 ml cartridge----1件: 78 💬
847NNC0195-0092 PDS290 10 mg-1.5 ml----1件: 78 💬
848NNC0195-0092 PDS290 10 mg/1.5 ml----1件: 78 💬
849NNC0215-0384----2件: 46, 162 💬
850NNC109-0012----1件: 46 💬
851NNC126-00831件: Somatropin pegol---1件: 78 💬
852NNC142-0002----1件: 96 💬
853NNC151-0000----1件: 46 💬
854Normal Saline 0.9% Infusion Solution----1件: 22 💬
855NovoNorm 0.5 mg----1件: 299 💬
856NP031112 800mg----1件: 5 💬
857NPB-01----3件: 13, 14, 162 💬
858NPC-02----1件: 171 💬
859NPC-09----1件: 30 💬
860NPI-001----2件: 90, 303 💬
861NS-065/NCNP-01----1件: 113 💬
862NS-089/NCNP-02----1件: 113 💬
863NT-KO-003----1件: 13 💬
864Obatoclax mesylate (GX15-070MS)1件: Obatoclax---1件: 60 💬
865OCA 0.1 mg----1件: 296 💬
866OCA 0.1mg----1件: 296 💬
867OCTAGAM 50 mg/ml oldatos infúzió----1件: 65 💬
868Octreotide a azione pronta 0,1 mg1件: Octreotide1件: Octreotide 💬1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 227 💬
869ODSH at 0.125 mg/kg/h----1件: 210 💬
870ODSH at 0.250 mg/kg/h----1件: 210 💬
871ODSH at 0.375 mg/kg/h----1件: 210 💬
872OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299 💬
873OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299 💬
874OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation----1件: 299 💬
875Olumiant - EU/1/16/1170/001-0081件: Baricitinib1件: Baricitinib 💬2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 49 💬
876Olumiant - EU/1/16/1170/009-0161件: Baricitinib1件: Baricitinib 💬2件: JAK1,
JAK2 💬
35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 49 💬
877OM 89.----1件: 46 💬
878Omalizumab (Xolair)1件: Omalizumab1件: Omalizumab 💬1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 65 💬
879Omaveloxolone Capsules, 80 mg1件: Omaveloxolone1件: Omaveloxolone 💬1件: NFE2L2 💬7件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬1件: 18 💬
880ON 01910.NA----1件: 36 💬
881Onasemnogene Abeparvovec-xioi1件: Onasemnogene abeparvovec1件: Onasemnogene abeparvovec 💬1件: SMN1 💬-1件: 3 💬
882Ondansetron 8 mg film-coated tablets1件: Ondansetron1件: Ondansetron 💬5件: HTR3A,
HTR3B,
HTR3C,
HTR3D,
HTR3E 💬
2件: Serotonergic synapse, Taste transduction 💬1件: 6 💬
883Open-label PTH(1-84)----1件: 235 💬
884OPRX-106 (plant cells expressing TNFR-Fc) 8mg----1件: 97 💬
885Oral Methylprednisolone 625 mg/24h x3 days1件: Methylprednisolone1件: Methylprednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 13 💬
886Orally disintegrating selegiline (Zelapar)1件: Selegiline1件: Selegiline 💬1件: MAOB 💬14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6 💬
887Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg3件: Estradiol,
Ethinylestradiol,
Norgestimate
3件: Estradiol ,
Ethinyl estradiol ,
Norgestimate 💬
3件: ESR1,
ESR2,
PGR 💬
12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 299 💬
888OSSM-001----1件: 96 💬
889Ozanimod 0.5 mg1件: Ozanimod1件: Ozanimod 💬5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
890P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),2件: Pramipexole,
Rasagiline
3件: Pramipexole ,
Rasagiline ,
Rasagiline tartrate 💬
4件: DRD2,
DRD3,
DRD4,
MAOB 💬
18件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
891P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),2件: Pramipexole,
Rasagiline
3件: Pramipexole ,
Rasagiline ,
Rasagiline tartrate 💬
4件: DRD2,
DRD3,
DRD4,
MAOB 💬
18件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
892Panzytrat 25.000----1件: 298 💬
893Panzytrat 25.000 FIP-E units of Lipase----1件: 298 💬
894Panzytrat® 25,000----1件: 299 💬
895Paracetamolo Zentiva Italia----1件: 28 💬
896Parathyroid hormon 1-84----1件: 235 💬
897Parathyroid Hormone (1-84) Human Recombinant1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
898Part 1, JM-010 component Group A----1件: 6 💬
899Part 1, JM-010 component Group B----1件: 6 💬
900Part 1, JM-010 component Group C----1件: 6 💬
901Part 2, JM-010 combination Group A----1件: 6 💬
902Part 2, JM-010 combination Group B----1件: 6 💬
903Part 2, JM-010 component Group C----1件: 6 💬
904Pasireotide 0.3mg1件: Pasireotide1件: Pasireotide 💬4件: SSTR1,
SSTR2,
SSTR3,
SSTR5 💬
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
905Pasireotide 0.6 MG/ML1件: Pasireotide1件: Pasireotide 💬4件: SSTR1,
SSTR2,
SSTR3,
SSTR5 💬
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
906Pasireotide 0.6mg1件: Pasireotide1件: Pasireotide 💬4件: SSTR1,
SSTR2,
SSTR3,
SSTR5 💬
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
907Pasireotide 0.9 mg1件: Pasireotide1件: Pasireotide 💬4件: SSTR1,
SSTR2,
SSTR3,
SSTR5 💬
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
908PAT-001, 0.1%----1件: 160 💬
909PAT-001, 0.2%----1件: 160 💬
910PD 0299685----1件: 226 💬
911PD 0299685 at 15mg BID----1件: 226 💬
912PD 0299685 at 30mg BID----1件: 226 💬
913PD 0360324----2件: 46, 84 💬
914PD-02996851件: PD-0299685---1件: 226 💬
915PD-03259011件: Mirdametinib1件: Mirdametinib 💬2件: MAP2K1,
MAP2K2 💬
89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 34 💬
916PF 06687234----2件: 96, 97 💬
917PF-004897911件: PF-00489791---1件: 86 💬
918PF-00547659----2件: 96, 97 💬
919PF-00547659 SC injection----2件: 96, 97 💬
920PF-02545920----1件: 8 💬
921PF-04171327----1件: 46 💬
922PF-04171327 10 mg----1件: 46 💬
923PF-04171327 25 mg----1件: 46 💬
924PF-04236921----2件: 49, 96 💬
925PF-04236921 SC injection----1件: 96 💬
926PF-04383119----1件: 226 💬
927PF-05208763----1件: 67 💬
928PF-05230917----1件: 97 💬
929PF-05280586----1件: 46 💬
930PF-05285401----1件: 97 💬
931PF-062526161件: Domagrozumab1件: Domagrozumab 💬1件: MSTN 💬1件: Cytokine-cytokine receptor interaction 💬1件: 113 💬
932PF-06291826-83/Fx-1006A1件: Fx-1006A---1件: 28 💬
933PF-06342674 0.25 mg/kg----1件: 13 💬
934PF-06342674 1.5 mg/kg----1件: 13 💬
935PF-06342674 6.0 mg/kg----1件: 13 💬
936PF-06410293----1件: 46 💬
937PF-06412562----1件: 6 💬
938PF-06438179----1件: 46 💬
939PF-06462700----1件: 60 💬
940PF-06480605----1件: 97 💬
941PF-06480605 100 mg/ml----1件: 97 💬
942PF-066497511件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
943PF-06649751 - 15mg1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
944PF-06649751 - 1mg1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
945PF-06649751 - 5mg1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
946PF-06649751 high dose (15 mg QD)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
947PF-06649751 low dose (1 mg QD)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
948PF-06649751 middle dose 1 (3 mg QD)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
949PF-06649751 middle dose 2 (7 mg QD)1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
950PF-066508331件: PF-06650833---1件: 46 💬
951PF-06650833 100 mg1件: PF-06650833---1件: 46 💬
952PF-06650833 20 mg1件: PF-06650833---1件: 46 💬
953PF-066516001件: PF-06651600---3件: 46, 96, 97 💬
954PF-06651600 10 mg1件: PF-06651600---1件: 97 💬
955PF-06651600 50 mg1件: PF-06651600---2件: 96, 97 💬
956PF-06651600 50mg1件: PF-06651600---1件: 96 💬
957PF-06651600-151件: PF-06651600---2件: 96, 97 💬
958PF-06669571----1件: 6 💬
959PF-06687234----1件: 97 💬
960PF-067008411件: PF-06700841---3件: 49, 96, 97 💬
961PF-06700841 15 mg1件: PF-06700841---1件: 49 💬
962PF-06700841 25 mg1件: PF-06700841---2件: 96, 97 💬
963PF-06700841 25mg1件: PF-06700841---1件: 49 💬
964PF-06700841 30 mg1件: PF-06700841---1件: 49 💬
965PF-06700841 45 mg1件: PF-06700841---1件: 49 💬
966PF-06700841 5 mg1件: PF-06700841---3件: 49, 96, 97 💬
967PF-06700841 5mg1件: PF-06700841---1件: 49 💬
968PF-06700841-151件: PF-06700841---3件: 49, 96, 97 💬
969PF-06730512----1件: 222 💬
970PF-06755347 intravenous healthy participant----1件: 63 💬
971PF-06755347 subcutaneous healthy participant----1件: 63 💬
972PF-06755347 subcutaneous ITP----1件: 63 💬
973PF-06823859----1件: 50 💬
974PF-06823859 high----1件: 50 💬
975PF-06823859 low----1件: 50 💬
976PF-06826647----1件: 97 💬
977PF-06826647 100 mg QD----1件: 97 💬
978PF-06826647 300 mg QD----1件: 97 💬
979PF-06826647 600 mg QD----1件: 97 💬
980PF-06835375----3件: 46, 49, 63 💬
981PF-06836922----1件: 78 💬
982PF-06939926----1件: 113 💬
983PF-07054894----1件: 97 💬
984PF-07256472----1件: 276 💬
985PHA-022121----1件: 65 💬
986PHA-022121 high dose----1件: 65 💬
987PHA-022121 low dose----1件: 65 💬
988PHA-022121 medium dose----1件: 65 💬
989PHA-022121 selected dose----1件: 65 💬
990Phenylalanine-free protein substitute in tablet form (XPhe minis)1件: Phenylalanine1件: Phenylalanine 💬--1件: 240 💬
991PI-08241件: PI-0824---1件: 35 💬
992Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie1件: Tazobactam1件: Tazobactam 💬--1件: 299 💬
993Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie1件: Tazobactam1件: Tazobactam 💬--1件: 299 💬
994Pirepemat x fumarate----1件: 6 💬
995PL 00095/5079R----1件: 46 💬
996PL 0010/0211----1件: 299 💬
997PL 00512/0150----1件: 298 💬
998PL 04515/0127----1件: 13 💬
999PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION)1件: Water1件: Water 💬--1件: 57 💬
1000PL 12762/0049----1件: 13 💬
1001PL 17901/0122----1件: 96 💬
1002PL 20532/0012----1件: 96 💬
1003PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE1件: Peginterferon beta-1a1件: Peginterferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1004Pleneva TM BGC20-0134----1件: 13 💬
1005PLN-74809-0001件: PLN-74809---1件: 85 💬
1006PLN-74809-0201件: PLN-74809---1件: 85 💬
1007Plovamer acetate 0.5 milligram (mg)1件: Acetate---1件: 13 💬
1008Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F----1件: 46 💬
1009PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml----2件: 62, 66 💬
1010PR-06410293----1件: 46 💬
1011Pramipexole 0.125 mg tablets1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1012Pramipexole 0.5 mg tablets1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1013Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1014Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1015Prednisone 0,5 mg/kg orally on alternate days1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 222 💬
1016PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen,
Streptococcus pneumoniae type 14 capsular polysaccharide antigen,
Streptococcus pneumoniae type 18c capsular polysaccharide antigen,
Streptococcus pneumoniae type 19a capsular polysaccharide antigen,
Streptococcus pneumoniae type 19f capsular polysaccharide antigen,
Streptococcus pneumoniae type 23f capsular polysaccharide antigen,
Streptococcus pneumoniae type 3 capsular polysaccharide antigen,
Streptococcus pneumoniae type 4 capsular polysaccharide antigen,
Streptococcus pneumoniae type 5 capsular polysaccharide antigen,
Streptococcus pneumoniae type 6b capsular polysaccharide antigen,
Streptococcus pneumoniae type 7f capsular polysaccharide antigen,
Streptococcus pneumoniae type 9v capsular polysaccharide antigen
---1件: 222 💬
1017PRM-151 (Zinpentraxin Alfa)1件: PRM-151---1件: 85 💬
1018PRO045, 0.15 mg/kg/week1件: BMN-045---1件: 113 💬
1019PRO045, 1.0 mg/kg/week1件: BMN-045---1件: 113 💬
1020PRO045, 3.0 mg/kg/week1件: BMN-045---1件: 113 💬
1021PRO045, 6.0 mg/kg/week1件: BMN-045---1件: 113 💬
1022PRO045, 9.0 mg/kg/week1件: BMN-045---1件: 113 💬
1023Profilassi per Herpes Zoster----1件: 107 💬
1024Prototype capsule GDC-01341件: GDC-0134---1件: 2 💬
1025PRTX-100 at 12.0 mcg/kg----1件: 46 💬
1026PRTX-100 at 3.0 mcg/kg----1件: 46 💬
1027PRTX-100 at 6.0 mcg/kg----1件: 46 💬
1028PT320 2.0 mg----1件: 6 💬
1029PTC-0161480----2件: 246, 299 💬
1030PTH1-84 in parent study----1件: 235 💬
1031PTI-8011件: PTI-801---1件: 299 💬
1032PTI-808----1件: 299 💬
1033PTR-01----1件: 36 💬
1034PTW-002 10 mg/g gel----1件: 36 💬
1035PUR 0110----1件: 97 💬
1036PUR 0110 Rectal Enema----1件: 97 💬
1037PUR 0110 Rectal Enema 1000 mg----1件: 97 💬
1038PUR 0110 Rectal Enema 250 mg----1件: 97 💬
1039PUR 0110 Rectal Enema 500 mg----1件: 97 💬
1040PZN 8881655(RochePharma AG)----1件: 85 💬
1041QCC374 0.015 mg----1件: 86 💬
1042QCC374 0.06 mg----1件: 86 💬
1043Qing Re Huo Xue (QRHX)----1件: 46 💬
1044QLS-101 ophthalmic solution, 2.0 %----1件: 157 💬
1045QR-010----1件: 299 💬
1046QRL-201- Dose 8----1件: 2 💬
1047QTXEW2-04-AF, EW2, GC-1, QRX-431----1件: 20 💬
1048Qutenza (8% capsaicin)1件: Capsaicin1件: Capsaicin 💬1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 86 💬
1049R-021----1件: 222 💬
1050R788 sodium hexahydrate, RIG2-01, RIG-G----1件: 46 💬
1051RAAV2/6 Left ZFN Vector----1件: 19 💬
1052RAAV2/6 Right ZFN Vector----1件: 19 💬
1053Raltegravir and Zidovudine2件: Raltegravir,
Zidovudine
2件: Zidovudine ,
Raltegravir 💬
--1件: 26 💬
1054Ranibizumab injection (0.5 mg)1件: Ranibizumab1件: Ranibizumab 💬1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬2件: 166, 301 💬
1055Rapamycin cream, topical, 0.5%, 1.0% w/w1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 158 💬
1056Rasagiline mesylate 1.0 mg1件: Rasagiline2件: Rasagiline ,
Rasagiline tartrate 💬
1件: MAOB 💬14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6 💬
1057RAvPAL-PEG 0.001 mg/kg1件: Pegvaliase1件: Pegvaliase 💬1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240 💬
1058RAvPAL-PEG 0.003 mg/kg1件: Pegvaliase1件: Pegvaliase 💬1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240 💬
1059RAvPAL-PEG 0.01 mg/kg1件: Pegvaliase1件: Pegvaliase 💬1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240 💬
1060RAvPAL-PEG 0.03 mg/kg1件: Pegvaliase1件: Pegvaliase 💬1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240 💬
1061RAvPAL-PEG 0.1 mg/kg1件: Pegvaliase1件: Pegvaliase 💬1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240 💬
1062RC18 80 mg plus standard therapy----1件: 49 💬
1063Rcombinant Human Parathyroid Hormone [rhPTH(1-84)]1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
1064RE-021----3件: 66, 218, 222 💬
1065RE-021 (Sparsentan)1件: Sparsentan1件: Sparsentan 💬2件: AGTR1,
EDNRA 💬
17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
1066RE-024----1件: 120 💬
1067REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1068Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1069Rebif 8,8 µg, Rebif 22µg1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1070Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1071Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack.1件: Interferon beta-1a1件: Interferon beta-1a 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
1072Recombinant coagulation FVIII Fc – von Willebrand factor – XTEN fusion protein1件: Von Willebrand factor human---1件: 288 💬
1073Recombinant coagulation FVIII Fc –von Willebrand factor – XTEN fusion protein1件: Von Willebrand factor human---1件: 288 💬
1074Recombinant Factor XIII1件: Factor XIII (human)---1件: 288 💬
1075Recombinant Factor XIII (rFXIII)1件: Factor XIII (human)---2件: 97, 288 💬
1076Recombinant human anti-GDF-8 antibody----1件: 113 💬
1077RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - XTEN FUSION PROTEIN3件: Antihemophilic factor human,
Beroctocog alfa,
Von Willebrand factor human
---1件: 288 💬
1078RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR -XTEN FUSION PROTEIN3件: Antihemophilic factor human,
Beroctocog alfa,
Von Willebrand factor human
---1件: 288 💬
1079RECOMBINANT HUMAN PARATHYROID HORMONE (1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
1080Recombinant Human Parathyroid Hormone [rhPTH(1-84)]1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
1081Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg----1件: 331 💬
1082Recombinant zoster vaccine----2件: 13, 49 💬
1083Red Blood Cell Zn----1件: 299 💬
1084REF CRUZADA PEI Nº 12-088----1件: 274 💬
1085Reference capsule GDC-01341件: GDC-0134---1件: 2 💬
1086REQUIP 21 CPR 0,25 MG1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1087REQUIP 21 CPR 0,5 MG1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1088Requip Modutab, 8mg1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1089Requip XL prolonged-release2件: Manganese citrate,
Ropinirole
1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1090REQUIP*21CPR 0,25MG1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1091REQUIP*21CPR 0,5MG1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1092REQUIP*28CPR 8MG R.P.1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1093REQUIP-MODUTAB , 8mg1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1094REQUIP-MODUTAB, 8mg1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1095REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML1件: Sildenafil1件: Sildenafil 💬1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 294 💬
1096Revatio 0.8mg/ml solution for injection1件: Sildenafil1件: Sildenafil 💬1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 294 💬
1097Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir3件: Abacavir,
Lamivudine,
Zidovudine
3件: Lamivudine ,
Zidovudine ,
Abacavir 💬
--1件: 325 💬
1098RG-012----1件: 218 💬
1099RGB-03----1件: 46 💬
1100RhPTH (1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
1101RhPTH(1-84)1件: Parathyroid hormone1件: Parathyroid hormone 💬2件: PTH1R,
PTH2R 💬
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬1件: 235 💬
1102RI-002----1件: 65 💬
1103Rifampin 300mg BID + istradefylline 40mg Day 8 only2件: Istradefylline,
Rifampicin
2件: Rifampin ,
Istradefylline 💬
1件: ADORA2A 💬7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬1件: 6 💬
1104Rifaximin 550 MG Oral Tablet [XIFAXAN]1件: Rifaximin1件: Rifaximin 💬--1件: 299 💬
1105Riociguat coated tablet 0.5 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 51 💬
1106Riociguat coated tablet 1.0 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 51 💬
1107Riociguat coated tablet 2.0 mg1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 51 💬
1108Riociguat granules 0.3% for oral application1件: Riociguat1件: Riociguat 💬3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86 💬
1109Rituximab-EU+ Rituximab-Pfizer x 2 Courses1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
1110Rituximab-Pfizer (PF-05280586) x 3 courses1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
1111Rituximab-US + Rituximab-Pfizer x 2 Courses1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
1112Ro 001-9265----1件: 41 💬
1113Ro 001-9265/F02----1件: 41 💬
1114RO 001-9265/F02-01----1件: 46 💬
1115Ro 001-9265/F03----1件: 41 💬
1116Ro 001-9265/F04----1件: 41 💬
1117Ro 002-9893/F02----1件: 46 💬
1118Ro 47-0203----4件: 51, 85, 86, 88 💬
1119Ro 47-0203 / ACT-050088----1件: 86 💬
1120Ro 487-7533/F10-02----1件: 46 💬
1121Ro 487-7533/F10-04----4件: 41, 46, 51, 107 💬
1122Ro 533-3787/F01- 06----1件: 13 💬
1123Ro 533-3787/F01-06----1件: 11 💬
1124Ro 549-0261/F04----1件: 97 💬
1125Ro 549-0261/F04-02----1件: 96 💬
1126Ro 549-0261/F08-02----1件: 96 💬
1127Ro-47-0203----1件: 86 💬
1128Ro-47-0203/029----1件: 86 💬
1129Ro47-0203----1件: 86 💬
1130Ro47-0203 / ACT-050088----2件: 51, 86 💬
1131RO487-7533/F10-04----2件: 46, 51 💬
1132RO4917523 0.5 mg----1件: 206 💬
1133RO4964913/F07-01----1件: 13 💬
1134Ro549-0261/F04-02----1件: 96 💬
1135RO5490255/F01-02----1件: 85 💬
1136RO5490261/F04-02----1件: 97 💬
1137RO7112689/F03-01----2件: 62, 109 💬
1138RO7123520/F03-01----1件: 46 💬
1139RO7204239/F01-01----1件: 3 💬
1140RO7248824/F02-01----1件: 201 💬
1141RO7248824/F03-01 (Diluent for RO7248824/F02-01----1件: 201 💬
1142RO7490677 160 mg/8 ml----1件: 85 💬
1143RO7490677 160 mg/8mL----1件: 85 💬
1144RO7490677 160mg/8mL----1件: 85 💬
1145RO7490677/ F01-02----1件: 85 💬
1146RO7490677/F01-01----1件: 85 💬
1147RO7490677/F01-02----1件: 85 💬
1148RO7490677/F01-03----1件: 85 💬
1149ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 51 💬
1150Rob 803----1件: 46 💬
1151Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali----1件: 46 💬
1152Rob 803 (capsules 12.5 mg)----1件: 46 💬
1153Rob 803 (capsules 15 mg)----1件: 46 💬
1154Rob 803 (capsules 25 mg)----1件: 46 💬
1155Rob 803 (capsules 6.25 mg)----1件: 46 💬
1156Rob 803 12.5mg capsule----1件: 46 💬
1157Rob 803 15mg capsule----1件: 46 💬
1158Rob 803 25mg capsule----1件: 46 💬
1159Rob 803 6.25mg capsule----1件: 46 💬
1160Rob 803 6.5mg capsule----1件: 46 💬
1161Ropinirole CR 8mg tablet1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1162Ropinirole PR/XR1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1163Ropinirole PR/XR Tablets1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1164Ropinirole prolonged release/extended release(PR/XR)1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1165Ropinirole XL1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1166Ropinirole XL (formerly CR)1件: Ropinirole1件: Ropinirole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1167Rosiglitazone XR1件: Rosiglitazone1件: Rosiglitazone 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 46 💬
1168ROT-TDS 8 mg/24 h----1件: 6 💬
1169Rotigotine transdermal patch 8mg/24h (40cm2)1件: Rotigotine1件: Rotigotine 💬1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1170RQ-00000010----1件: 6 💬
1171RST-001----1件: 90 💬
1172RVG 03820----1件: 3 💬
1173RVG 05565----1件: 96 💬
1174RVG 07151----1件: 96 💬
1175RVG 08740----1件: 6 💬
1176RVG 08938----1件: 75 💬
1177RWJ-445380-002----1件: 46 💬
1178SA-001----1件: 298 💬
1179SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE1件: Somatotropin---1件: 78 💬
1180Saizen 8mg click.easy powder for solution for injection1件: Somatotropin---1件: 78 💬
1181Saizen 8mg click.easy power for solution for injection1件: Somatotropin---1件: 78 💬
1182Saline 0.9% inhalation solution----1件: 299 💬
1183Saline 0.9% NaCl----1件: 235 💬
1184SAN-300 0.5 mg/kg QW----1件: 46 💬
1185SAN-300 1.0 mg/kg QW----1件: 46 💬
1186SAN-300 2.0 mg/kg QOW----1件: 46 💬
1187SAN-300 4.0 mg/kg QOW----1件: 46 💬
1188SAN-300 4.0 mg/kg QW----1件: 46 💬
1189SBI-087----2件: 46, 49 💬
1190SBT-020----1件: 8 💬
1191SCM-010----1件: 13 💬
1192SD-101-6.0 cream----1件: 36 💬
1193SD-809----1件: 8 💬
1194Search for exocrine pancreatic insufficiency at week 0 and 12----1件: 96 💬
1195Sebelipase alfa 0.35 mg/kg1件: Sebelipase alfa1件: Sebelipase alfa 💬1件: LIPA 💬3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬1件: 19 💬
1196Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.1件: Secukinumab1件: Secukinumab 💬1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
1197Secukinumab 75 mg/0.5 ml Solution for injection1件: Secukinumab1件: Secukinumab 💬1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
1198Serum physiologique 0.9 %----1件: 96 💬
1199Serum Zn----1件: 299 💬
1200Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane----1件: 96 💬
1201SGT-001----1件: 113 💬
1202Sifrol 0,0881件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1203Sifrol 0,181件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1204Sifrol 0,351件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1205Sifrol 0,71件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1206Sifrol, 0,35 mg Tablette1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1207Sifrol, 0,70 mg Tablette1件: Pramipexole1件: Pramipexole 💬3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
1208SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE1件: Golimumab1件: Golimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
1209Single dose C2N-8E12----1件: 5 💬
1210Siponimod 0,25 mg1件: Siponimod1件: Siponimod 💬2件: S1PR1,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
1211Siponimod 0.25 mg tablet1件: Siponimod1件: Siponimod 💬2件: S1PR1,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬2件: 13, 50 💬
1212Siponimod 0.5 mg tablet1件: Siponimod1件: Siponimod 💬2件: S1PR1,
S1PR5 💬
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬2件: 13, 50 💬
1213Sirolimus 0,1% crème1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬2件: 278, 280 💬
1214Sirolimus 0.2%1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 158 💬
1215Sirolimus 0.4%1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 158 💬
1216SLS-005----1件: 2 💬
1217SLS-005 Trehalose1件: Trehalose---1件: 2 💬
1218Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca----1件: 299 💬
1219Sodium butyrate and zinc oxide2件: Butyric Acid,
Zinc oxide
1件: Zinc oxide 💬--1件: 156 💬
1220Sodium chloride 0,9%2件: Chloride ion,
Sodium chloride
1件: Sodium chloride 💬--1件: 299 💬
1221Sodium Chloride 0.9%2件: Chloride ion,
Sodium chloride
1件: Sodium chloride 💬--2件: 14, 227 💬
1222SODIUM CHLORIDE SOLUTION 0.9%2件: Chloride ion,
Sodium chloride
1件: Sodium chloride 💬--4件: 51, 60, 288, 299 💬
1223Sodium Pyruvate in 0.9% Sodium Chloride Solution2件: Chloride ion,
Sodium chloride
1件: Sodium chloride 💬--1件: 299 💬
1224SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML----1件: 56 💬
1225Somatic gene-therapy by X-CGD----1件: 65 💬
1226SPI-1005 Ebselen 200mg Capsule x11件: Ebselen---1件: 299 💬
1227SPI-1005 Ebselen 200mg Capsule x21件: Ebselen---1件: 299 💬
1228SPI-1005 Ebselen 200mg Capsule x31件: Ebselen---1件: 299 💬
1229SPP-004----1件: 21 💬
1230SRK-015----1件: 3 💬
1231SSP-004184 100 mg----1件: 284 💬
1232SSP-004184 100 mg Capsule----1件: 284 💬
1233SSP-004184 250 mg----1件: 284 💬
1234SSP-004184 250 mg Capsule----1件: 284 💬
1235SSP-004184 375 mg----1件: 284 💬
1236SSP-004184 375 mg Capsule----1件: 284 💬
1237SSP-004184 50 mg----1件: 284 💬
1238SSP-004184 50 mg Capsule----1件: 284 💬
1239SSP-004184 500 mg----1件: 284 💬
1240SSP-004184 500 mg Capsule----1件: 284 💬
1241SSP-004184AQ 100 mg----1件: 284 💬
1242SSP-004184AQ 100 mg Capsule----1件: 284 💬
1243SSP-004184AQ 200 mg----1件: 284 💬
1244SSP-004184AQ 200 mg Capsule----1件: 284 💬
1245SSP-004184AQ 250 mg----1件: 284 💬
1246SSP-004184AQ 250 mg Capsule----1件: 284 💬
1247SSP-004184AQ 375 mg----1件: 284 💬
1248SSP-004184AQ 375 mg Capsule----1件: 284 💬
1249SSP-004184AQ 50 mg----1件: 284 💬
1250SSP-004184AQ 50 mg Capsule----1件: 284 💬
1251ST-0529----1件: 97 💬
1252ST10-021----2件: 96, 97 💬
1253Standard Dose YPT-01----1件: 299 💬
1254STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO1件: Ustekinumab1件: Ustekinumab 💬3件: IL12A,
IL12B,
IL23A 💬
28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬1件: 96 💬
1255STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO1件: Ustekinumab1件: Ustekinumab 💬3件: IL12A,
IL12B,
IL23A 💬
28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬2件: 96, 97 💬
1256Sterile Normal Saline (0.9% NaCl)----2件: 62, 254 💬
1257STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V)----1件: 299 💬
1258STG-0011件: STG-001---1件: 301 💬
1259STK-0011件: Zorevunersen---1件: 140 💬
1260STK-001 - Multiple Ascending Doses1件: Zorevunersen---1件: 140 💬
1261STK-001 - Single Ascending Doses1件: Zorevunersen---1件: 140 💬
1262STNM01 1.84 mg----1件: 97 💬
1263Sulindac (HLX-0201), dose strength 11件: Sulindac1件: Sulindac 💬2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 206 💬
1264Sulindac (HLX-0201), dose strength 21件: Sulindac1件: Sulindac 💬2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 206 💬
1265T-817MA----1件: 149 💬
1266TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE----1件: 14 💬
1267TAK-018----1件: 96 💬
1268TAK-071----1件: 6 💬
1269TAK-079----3件: 11, 49, 63 💬
1270TAK-079, TSF-021, TSF79----1件: 11 💬
1271TAK-8311件: TAK-831---1件: 18 💬
1272Taltz (80 mg solution for injection in pre-filled syringe)1件: Ixekizumab1件: Ixekizumab 💬1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬2件: 107, 271 💬
1273Taltz 80mg1件: Ixekizumab1件: Ixekizumab 💬1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 36 💬
1274Tavapadon 0.25 mg1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
1275Tavapadon 0.25mg1件: Tavapadon1件: Tavapadon 💬2件: DRD1,
DRD5 💬
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬1件: 6 💬
1276Teduglutide (ALX-0600)1件: Teduglutide1件: Teduglutide 💬1件: GLP2R 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
1277Teduglutide 0.051件: Teduglutide1件: Teduglutide 💬1件: GLP2R 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
1278Teduglutide 0.05 dose1件: Teduglutide1件: Teduglutide 💬1件: GLP2R 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
1279Teduglutide 0.1 mg dose1件: Teduglutide1件: Teduglutide 💬1件: GLP2R 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
1280Teduglutide 0.2 mg1件: Teduglutide1件: Teduglutide 💬1件: GLP2R 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96 💬
1281Telitacicept 80 mg----1件: 53 💬
1282Terguride 0,5mg tablet1件: Terguride1件: Terguride 💬2件: DRD2,
PRL 💬
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86 💬
1283Terguride 0.5 mg tablet1件: Terguride1件: Terguride 💬2件: DRD2,
PRL 💬
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86 💬
1284TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML----1件: 222 💬
1285The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide----1件: 222 💬
1286The effectiveness of Xeljanz in rheumatoid arthritis patients1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
1287The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent.----1件: 96 💬
1288The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA----1件: 96 💬
1289The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA.----1件: 96 💬
1290Timolol Alcon 0.5% collyre1件: Timolol2件: Timolol ,
Timolol 💬
2件: ADRB1,
ADRB2 💬
11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 227 💬
1291TLL-018----1件: 46 💬
1292TLR7/8 Antagonist (10mg)----1件: 49 💬
1293TLR7/8 Antagonist (2.5mg)----1件: 49 💬
1294TMI-005----1件: 46 💬
1295TMI-005 (WAY-177005)----1件: 46 💬
1296TMI-005 WAY-177005----1件: 46 💬
1297TNR-001----2件: 46, 271 💬
1298TNR-001, TNFR:FC----1件: 271 💬
1299TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation1件: Tobramycin1件: Tobramycin 💬--1件: 299 💬
1300Tocilizumab 162Mg/0.9Ml Autoinjector1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
1301Tocilizumab 162mg/0.9ml jeringa SC1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1302Tocilizumab 162mg/0.9ml SC PFS SC1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1303Tocilizumab 162mg/0.9ml syringe SC1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1304Tocilizumab Injection 8mg/kg1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1305Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI)1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1306Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS)1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
1307Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS)1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 51 💬
1308Tofacitinib (Xeljanz)1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
1309Tofacitinib (Xeljanz®)1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
1310Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
1311Tofacitinib 10 MG [Xeljanz]1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 97 💬
1312Tofacitinib 5 MG [Xeljanz]1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬2件: 46, 50 💬
1313Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 84 💬
1314Tofacitinib XR1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬2件: 46, 271 💬
1315Topical 0.1% Sirolimus1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 278 💬
1316Topical BPM31510 3.0% Cream----1件: 36 💬
1317Topical calcipotriene 0.005% ointment1件: Calcipotriol1件: Calcipotriene 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 51 💬
1318Trade Name Xarelto1件: Rivaroxaban1件: Rivaroxaban 💬1件: F10 💬1件: Complement and coagulation cascades 💬1件: 49 💬
1319Trametinib (0.5 mg)1件: Trametinib1件: Trametinib 💬2件: MAP2K1,
MAP2K2 💬
89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 2 💬
1320TransCon hGH (ACP-011)----1件: 78 💬
1321TransCon hGH (ACP-011) - 12,1mg----1件: 78 💬
1322TransCon hGH (ACP-011) - 12.1mg----1件: 78 💬
1323TransCon hGH (ACP-011) - 24.2mg----1件: 78 💬
1324TransCon hGH CT-301 (ACP-011) - 12,1mg----1件: 78 💬
1325Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 8401件: Treprostinil1件: Treprostinil 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
1326TRU-0151件: TRU-015---3件: 46, 49, 222 💬
1327Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere1件: Dulaglutide1件: Dulaglutide 💬1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 13 💬
1328Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere.1件: Dulaglutide1件: Dulaglutide 💬1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 13 💬
1329TVP-1012 0.5mg----1件: 6 💬
1330Twice-daily dosage with 0.5% cyclosporine-A eyedrops1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 90 💬
1331TY-0305----1件: 58 💬
1332UF-021----1件: 90 💬
1333UF-021 (isopropyl unoprostone)1件: Unoprostone1件: Unoprostone 💬1件: PTGFR 💬3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬1件: 90 💬
1334UF-021(isopropyl unoprostone)1件: Unoprostone1件: Unoprostone 💬1件: PTGFR 💬3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬1件: 90 💬
1335UK 092480----1件: 86 💬
1336UK-427,857----1件: 46 💬
1337UN-ALPHA-R 0.25µg----1件: 235 💬
1338Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)1件: Genistein1件: Genistein 💬--1件: 299 💬
1339UT-15C 0.25 mg----1件: 86 💬
1340UVADEX and UVAR XTS Photopheresis System1件: Methoxsalen1件: Methoxsalen 💬--1件: 96 💬
1341UVEDOSE 100 000 UI----1件: 13 💬
1342UVEDOSE 100 000 UI, solution buvable en ampoule----1件: 13 💬
1343UX701 (1.0 × 10^13 genome copies/kg)----1件: 171 💬
1344UX701 (2.0 × 10^13 genome copies/kg)----1件: 171 💬
1345UX701 (5.0 × 10^12 genome copies/kg)----1件: 171 💬
1346Vamorolone 0.25 mg/day/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1347Vamorolone 0.25 mg/kg/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1348Vamorolone 0.75 mg/day/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1349Vamorolone 0.75 mg/kg/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1350Vamorolone 2.0 mg/day/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1351Vamorolone 2.0 mg/kg/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1352Vamorolone 6.0 mg/day/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1353Vamorolone 6.0 mg/kg/day1件: Vamorolone1件: Vamorolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 113 💬
1354Varicella Zoster Vaccine----1件: 46 💬
1355Vedolizumab-800CW1件: Vedolizumab1件: Vedolizumab 💬2件: ITGA4,
ITGB7 💬
15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬1件: 96 💬
1356Vehicle (SD-101 0%)----1件: 36 💬
1357Ventoline oral solution 0,4mg/ml----1件: 111 💬
1358Vigantol® Öl 20.000 I.E./ml----1件: 13 💬
1359Vit C Vit E Zn Se----1件: 113 💬
1360Vitamin D3 800 UI/day then 800 UI/day1件: Cholecalciferol1件: Cholecalciferol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96 💬
1361Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day1件: Cholecalciferol1件: Cholecalciferol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 96 💬
1362Vitamin E 800IU1件: Vitamin E1件: Vitamin E 💬--2件: 96, 97 💬
1363VRT-813077----1件: 299 💬
1364VRT-826809----1件: 299 💬
1365VRT-893661----1件: 299 💬
1366VRT-893661 VRT-0893661----1件: 299 💬
1367VT-001----1件: 66 💬
1368VTX-801----1件: 171 💬
1369VX-661, VRT-893661----1件: 299 💬
1370VX-770, VRT-8130077----1件: 299 💬
1371VX-770, VRT-813077----1件: 299 💬
1372VX-809----1件: 299 💬
1373VX-809 & VX-770----1件: 299 💬
1374VX-809 / VX-770----1件: 299 💬
1375VX-809, VRT-826809----1件: 299 💬
1376VX-809/VX-770----1件: 299 💬
1377VX-814----1件: 231 💬
1378VX-864----1件: 231 💬
1379VYNT-0126----1件: 156 💬
1380White chocolate (0% cocoa)1件: Cocoa---1件: 6 💬
1381WVE-003----1件: 8 💬
1382WVE-004----2件: 2, 127 💬
1383X4P-001----1件: 65 💬
1384Xeljanz XR1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
1385XmAb5871_1.0MG----1件: 46 💬
1386XmAb5871_10.0MG----1件: 46 💬
1387XmAb5871_3.0MG----1件: 46 💬
1388Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung1件: Omalizumab1件: Omalizumab 💬1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 299 💬
1389XOMA 052----5件: 41, 46, 50, 56, 106 💬
1390YONDELIS 0,25 mg polvo para concentrado para solución para perfusión1件: Trabectedin1件: Trabectedin 💬--1件: 159 💬
1391Yondelis 0.25 mg powder for concentrate for solution for infusion.1件: Trabectedin1件: Trabectedin 💬--1件: 159 💬
1392Zanubrutinib 80 MG1件: Zanubrutinib1件: Zanubrutinib 💬1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬1件: 300 💬
1393ZAVESCA 84CPS 100MG1件: Miglustat1件: Miglustat 💬1件: UGCG 💬2件: Metabolic pathways, Sphingolipid metabolism 💬1件: 19 💬
1394Zolgensma 2 x 1013 vector genomes/mL solution for infusion1件: Onasemnogene abeparvovec1件: Onasemnogene abeparvovec 💬1件: SMN1 💬-1件: 3 💬
1395Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion1件: Onasemnogene abeparvovec1件: Onasemnogene abeparvovec 💬1件: SMN1 💬-1件: 3 💬
1396Zostavax (varicella zoster virus) vaccine1件: Varicella zoster vaccine (live/attenuated)---1件: 46 💬
1397ZX008 - 0.2 mg/kg/day----1件: 140 💬
1398ZX008 - 0.8 mg/kg/day----1件: 140 💬
1399ZX008 0.2 or 0.8 mg/kg/day----1件: 144 💬
1400ZX008 0.2 to 0.8 mg/kg/day----2件: 140, 144 💬